Autoimmune Disorders

The purpose of this study is to evaluate the safety of different doses of risankizumab and determine how well it works in subjects with moderate to severe Crohn’s disease.

Primary disease category: 
Secondary disease category(ies): 

The purpose of this study is to evaluate the safety of different doses of risankizumab and determine how well it works in subjects with moderate to severe Crohn disease.

Primary disease category: 
Secondary disease category(ies): 

JAHH is a Phase 2, multicenter, randomized, double-blind, placebo controlled, outpatient, 24-week study evaluating the efficacy and safety of baricitinib 4-mg and 2-mg in patients with SLE receiving standard therapy. Approximately 300 patients will be randomized 1:1:1 to receive baricitinib 4-mg daily, baricitinib 2-mg daily, or placebo (100 patients per treatment group).

Primary disease category: 
Subscribe to RSS - Autoimmune Disorders